In Section A, contributors will receive various doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. Extra individuals will be enrolled on the determined monotherapy dosign program. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Phase C, contributors https://howdoesabbv-744workincanc46801.idblogz.com/32559611/about-abbv-744-as-a-potential-therapeutic-option-for-aggressive-cancers